FMP
Zosano Pharma Corporation
ZSAN
NASDAQ
Inactive Equity
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
0.558 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
Description
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
CIK
0001587221
ISIN
US98979H2022
CUSIP
98979H202
Address
34790 Ardentech Ct
Phone
15107451200
Country
US
Employee
40
IPO Date
Jan 27, 2015
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ZSAN Financial Summary
CIK
0001587221
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
98979H202
ISIN
US98979H2022
Country
US
Price
0.56
Beta
3.29
Volume Avg.
5.36M
Market Cap
0
Shares
-
52-Week
0.46-0.635
DCF
1.1
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.94
P/B
-
Website
https://www.zosanopharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ZSAN News
It looks like there's no news available.
